Treatment of Depression in Parkinson's Disease Trial

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rutgers, The State University of New Jersey
• Collaborator: GlaxoSmithKline
• Treatments: Nortriptyline; Paroxetine

Criteria

inclusion criteria:

• Parkinson's disease without dementia.

• Depression.

• Males or females.

exclusion criteria:

• Psychosis

• Heart block